Read by QxMD icon Read

Clinical Breast Cancer

Erica L Gornstein, Sara Sandefur, Jon H Chung, Laurie M Gay, Oliver Holmes, Rachel L Erlich, Salil Soman, L Katherine Martin, Andrea V Rose, Philip J Stephens, Jeffrey S Ross, Vincent A Miller, Siraj M Ali, Sibel Blau
No abstract text is available yet for this article.
December 21, 2017: Clinical Breast Cancer
Nikiforita Poulakaki, Georgios-Marios Makris, Aristea-Maria Papanota, Filio Marineli, Alexandros Marinelis, Marco-Johannes Battista, Daniel Boehm, Amanda Psyrri, Theodoros N Sergentanis
BACKGROUND: Ki-67 is a marker of proliferating cells; in this meta-analysis we aimed to examine whether Ki-67 expression can predict recurrence rates of breast ductal carcinoma in situ (DCIS). MATERIALS AND METHODS: This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible articles were sought in MEDLINE up to April 30, 2017. Random effects (DerSimonian-Laird) models were used for the calculation of pooled relative risk (RR) estimates; meta-regression analysis was also performed...
December 16, 2017: Clinical Breast Cancer
Jane Meisel, Chao Zhang, Cameron Neely, Pia Mendoza, Shuo You, Tatiana Han, Yuan Liu, Aysegul A Sahin, Ruth O'Regan, Xiaoxian Li
INTRODUCTION: Hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancers without lymph node metastasis have good prognosis. We compared the prognosis of hormone receptor-positive, HER2-negative, lymph node-negative cancers with Oncotype DX score ranges of 1 to 10 (1-10 group) and 11 to < 18 (11-18 group). PATIENTS AND METHODS: A total of 107 cases in the 1-10 group and 225 cases in the 11-18 group were reviewed. All patients received surgery...
December 14, 2017: Clinical Breast Cancer
Gerhard J Molderings, Ruth Knüchel-Clarke, Hans-Jörg Hertfelder, Christiane Kuhl
No abstract text is available yet for this article.
December 12, 2017: Clinical Breast Cancer
Sayaka Kuba, Shigeto Maeda, Megumi Matsumoto, Kosho Yamanouchi, Hiroshi Yano, Michi Morita, Chika Sakimura, Toshiko Hatachi, Yukiko Tokai, Mitsuhisa Takatsuki, Hikaru Fujioka, Naomi Hayashida, Takeshi Nagayasu, Susumu Eguchi
INTRODUCTION: Nonadherence to adjuvant endocrine therapy has been poorly studied in Asian patients with breast cancer. We therefore assessed adherence to endocrine therapy among women with breast cancer in Japan. PATIENTS AND METHODS: We conducted a prospective observational study among Japanese women with hormone receptor-positive breast cancer. Patients brought their pill packets to visits for 1 year and answered a questionnaire. We also examined prescription records during the study period...
December 12, 2017: Clinical Breast Cancer
Yael Laitman, Dana Madorsky Feldman, Miri Sklair-Levy, Ady Yosepovich, Iris Barshack-Nakar, Malka Brodsky, Osnat Halshtok, Anat Shalmon, Michael Gotlieb, Eitan Friedman
BACKGROUND: High-risk BRCA mutation carriers are offered a surveillance scheme aimed at early detection of breast cancer. Although the efficacy of this scheme in breast cancer detection is well-established, the rate of breast cancer diagnosis of radiologically suspicious lesions and the effect of this screening scheme on breast cancer grade and stage are less well-defined. PATIENTS AND METHODS: Female BRCA1 and BRCA2 mutation carriers who were cancer-free at the beginning of follow-up at the Meirav High-risk Clinic, Sheba Medical Center, were eligible...
December 11, 2017: Clinical Breast Cancer
Akiko Chiba, Rachna Raman, Alexandra Thomas, Pierre-Jean Lamy, Marie Viala, Stephane Pouderoux, Sarah L Mott, Mary C Schroeder, Simon Thezenas, William Jacot
INTRODUCTION: There has been increasing interest in the potential benefit of vitamin D in improving breast cancer outcome. Preclinical studies suggest that vitamin D enhances chemotherapy-induced cell death. We investigated the impact of serum vitamin D levels during neoadjuvant chemotherapy (NAC) on the rates of achieving pathologic complete response (pCR) after breast cancer NAC. PATIENTS AND METHODS: Patients from 1 of 2 Iowa registries who had serum vitamin D level measured before or during NAC were included...
December 11, 2017: Clinical Breast Cancer
Karishma G Reddy, Paula D Strassle, Kandace P McGuire
BACKGROUND: Despite the psychological benefits and oncologic safety of postmastectomy breast reconstruction, most breast cancer patients do not undergo reconstruction. To better understand the patterns of breast reconstruction usage, it is important to identify the clinicopathologic factors associated with immediate breast reconstruction (IBR), and whether modification of the reconstruction incidence when stratified by patient- or cancer-related factors exists in the breast cancer population...
December 7, 2017: Clinical Breast Cancer
Eman A Elghoroury, Hesham G ElDine, Solaf A Kamel, Amany H Abdelrahman, Asmaa Mohammed, Mahmoud M Kamel, Mona H Ibrahim
BACKGROUND: Breast cancer remains one of the top threats to women's health. The current lack of tumor markers with desirable sensitivity and specificity is a major obstacle toward the future management of breast cancer. Many studies are directed to reveal the diagnostic and prognostic potentials of circulating miRNAs in breast cancer. In this study, we attempt to evaluate the feasibility and clinical utility of circulating miRNA-21 and let-7 as prognostic biomarkers for breast cancer...
December 7, 2017: Clinical Breast Cancer
Madelyn Mousa, Yoav Barnea, Udi Arad, Amir Inbal, Joseph Klausner, Tehillah Menes
INTRODUCTION: Mastectomy with immediate reconstruction is associated with increased complications when compared with mastectomy without reconstruction. Postoperative complications have been associated with worse oncologic outcome in other cancers. We examined the association between postoperative complications after immediate reconstruction and oncologic outcome. METHODS: This retrospective study included all women undergoing mastectomy and immediate alloplastic reconstruction for breast cancer between the years 2009 and 2016...
December 7, 2017: Clinical Breast Cancer
Manuel Scimeca, Chiara Antonacci, Nicola Toschi, Elena Giannini, Rita Bonfiglio, Claudio Oreste Buonomo, Chiara Adriana Pistolese, Umberto Tarantino, Elena Bonanno
BACKGROUND: The development of bone metastasis from breast cancer results from a functional interaction between tumor cells and osteoclasts or osteoblasts. The main aim of this study was therefore to test the hypothesis that the appearance of breast osteoblast-like cells (BOLCs) in primary mammary lesions is a precursor (and hence an early predictor) of the formation of breast cancer metastases to bone. PATIENTS AND METHODS: In this study, we collected 64 breast infiltrating carcinomas, 50 breast benignant lesions, and 10 biopsies of bone metastasis selected from patients with infiltrated carcinoma...
December 5, 2017: Clinical Breast Cancer
Leonardo Cattelani, Susanna Polotto, Maria Francesca Arcuri, Giuseppe Pedrazzi, Chiara Linguadoca, Elena Bonati
BACKGROUND: The breast reconstructive subpectoral technique commonly leads to functional consequences. Recently, a new conservative prepectoral breast reconstruction (PPBR) technique was proposed and its surgical safety and aesthetic effectiveness proved. The aim of this prospective nonrandomized study was to compare the functional and economical outcomes of the PPBR procedure versus the subpectoral one. PATIENTS AND METHODS: From February 2015 to September 2016, 86 patients underwent mastectomy with immediate implant-based reconstruction...
December 2, 2017: Clinical Breast Cancer
Leland E Hull, Julie A Lynch, Brygida B Berse, Scott L DuVall, Danielle S Chun, Vicki L Venne, Olga V Efimova, Michael S Icardi, Michael J Kelley
INTRODUCTION: Ensuring guideline-concordant cancer care is a Department of Veterans Affairs (VA) priority, especially as the number of breast cancer patients at VA medical centers (VAMCs) grows. We assessed the utilization and clinical impact of the 21-gene Recurrence Score test, which predicts 10-year risk of breast cancer recurrence and the likelihood of chemotherapy benefit, on veterans newly diagnosed with breast cancer. PATIENTS AND METHODS: We conducted a retrospective cohort study using 2011-2012 VA Central Cancer Registry, chart review, and laboratory test data...
November 29, 2017: Clinical Breast Cancer
Esther Bastiaannet, Jackie Charman, Tom Børge Johannesen, Simone Schrodi, Sabine Siesling, Liesbet van Eycken, Paul M Walsh, Riccardo A Audisio, Petra G Boelens, Isabel T Rubio, Nick Jones, Jan Lewis, Cornelis J H van de Velde
BACKGROUND: Despite guideline recommendations, reports suggest that a proportion of patients with hormone receptor (HR)-positive locally advanced or metastatic breast cancer (LA/MBC) might not receive endocrine therapy. The aims of this study were to estimate the proportion of postmenopausal patients with an initial (primary) diagnosis of HR-positive LA/MBC in Europe, and to assess the administration of endocrine treatment in these patients. MATERIALS AND METHODS: Fourteen national and regional cancer registries across Europe were invited to participate in this observational study...
November 29, 2017: Clinical Breast Cancer
Victoria C Hamelinck, Esther Bastiaannet, Arwen H Pieterse, Cornelis J H van de Velde, Gerrit-Jan Liefers, Anne M Stiggelbout
BACKGROUND: Older patients are believed to prefer a more passive role in treatment decision making, but studies reporting this relation were conducted over a decade ago or were retrospective. We prospectively compared younger (40-64 years) versus older (≥ 65 years) breast cancer patients' preferences for decision-making roles and their perceived actual roles. PATIENTS AND METHODS: A prospective multicenter study was conducted in Leiden, The Hague, and Tilburg over a 2-year period...
November 28, 2017: Clinical Breast Cancer
Yosef Landman, Maya Ilouze, Simon Wein, Victoria Neiman, Rinat Yerushalmi, Maxim Yakimov, Nora Ku, Alexa B Schrock, Siraj Ali, Nir Peled
No abstract text is available yet for this article.
November 28, 2017: Clinical Breast Cancer
Hong-Tai Chang, Hsiang-Ju Pan, Chien-Hung Lee
BACKGROUND: Tamoxifen is commonly used to prevent breast cancer recurrence. Studies have confirmed the association between tamoxifen and nonalcoholic fatty liver disease (NAFLD), with the results indicating the need for aggressive management of this side effect. We assessed the potential risk factors for and identified the possible protective factors of tamoxifen-related fatty liver. MATERIALS AND METHODS: We enrolled patients with a history of breast cancer, aged 20 to 70 years, who had received with tamoxifen treatment within the past 5 years...
November 23, 2017: Clinical Breast Cancer
Daniela Furrer, Simon Jacob, Annick Michaud, Louise Provencher, Julie Lemieux, Caroline Diorio
PURPOSE: Although the administration of trastuzumab has improved the survival of human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, resistance remains a major clinical obstacle. We retrospectively evaluated the association of HER2 polymorphisms, tobacco use and alcohol consumption with disease-free survival (DFS) in HER2-positive breast cancer patients. PATIENTS AND METHODS: Clinicopathologic and survival data (median follow-up, 7.4 years) were collected from medical records for 236 nonmetastatic trastuzumab-treated HER2-positive breast cancer patients...
November 23, 2017: Clinical Breast Cancer
Christina A Fleming, Karen McCarthy, Ciara Ryan, Aoife McCarthy, Seamus O'Reilly, Deirdre O'Mahony, Tara Jane Browne, Paul Redmond, Mark A Corrigan
BACKGROUND: Neoadjuvant therapy (NAT) offers a unique opportunity to assess tumor response to systemic agents. However, a discrepancy may exist between the response of the primary tumor and involved nodes. We report on the frequency of response discordance after NAT in breast cancer. PATIENTS AND METHODS: All consecutive node-positive patients receiving NAT in our department from 2009 to 2014 were identified. Patient demographics, and radiologic and pathologic features were tabulated...
November 23, 2017: Clinical Breast Cancer
Ishrat Rasool, Dil Afroze, Khursheed Alam Wani, Adfar Yousuf, Imtiyaz Ahmad Bhat, Bilal Rah, Sheeraz Un Nazir, Showket Hussain, Shweta Dubey
INTRODUCTION: Survivin is an apoptosis inhibitor and plays a primary role in cancer development and progression. One of the most common polymorphism of the survivin promoter -31G/C (rs9904341) influences its expression and is associated with the risk of cancer development. This study was conducted to explore survivin promoter gene -31G/C (rs9904341) polymorphism and the risk of breast cancer. PATIENTS AND METHODS: The study group included 190 pathologically confirmed breast cancer patients, in addition to 200 distinct cancer-free controls from Jammu and Kashmir region of India, where breast cancer is the most common cancer in women...
November 23, 2017: Clinical Breast Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"